** Shares of drug developer Kymera Therapeutics KYMR.O rise 39.16% to $41.25 premarket

** Company says its experimental oral drug showed robust STAT6 degradation in blood and skin in early-stage trial

** The drug, KT-621, targets STAT6 — a signaling protein that plays a key role in immune response

** Company says results exceeded 90% STAT6 degradation target even at single doses as low as 6.25 mg

** KT-621 impact on biomarkers of Th2 immune response were in line or superior to Sanofi SASY.PA and Regeneron's REGN.O Dupixent - KYMR

** The study finds that KT-621 was as safe as the placebo, with no severe adverse events

** Up to last close, Kymera stock down ~26% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))